Related Experiment Video

Updated: Aug 14, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

[Multidrug resistance of malignant tumors]

M Bak1

  • 1Citodiagnosztikai Osztály, Országos Onkológiai Intézet, Budapest.

Orvosi Hetilap
|October 6, 1991
PubMed

Insights

Multidrug resistance (MDR) in cancer involves cells resisting multiple chemotherapy drugs. Overexpression of P-glycoprotein, an efflux pump, is a key factor. Overcoming this pump may improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy resistance is a significant challenge in treating malignant tumors, leading to brief remissions and treatment failure.
  • Multidrug resistance (MDR) is characterized by cellular resistance to various structurally unrelated drugs.
  • Overexpression of a 170 kD glycoprotein, P-glycoprotein (P-170), encoded by the MDR gene family, is commonly observed in multidrug-resistant cells.

Purpose of the Study:

  • To investigate the role of P-glycoprotein in multidrug resistance.
  • To explore strategies for overcoming P-glycoprotein-mediated drug efflux.
  • To understand the clinical implications of multidrug resistance in cancer therapy.

Main Methods:

  • Analysis of P-glycoprotein expression in multidrug-resistant cancer cells.
  • Investigation of P-glycoprotein's function as an energy-dependent drug efflux pump.
  • Evaluation of pharmacological approaches to circumvent P-glycoprotein activity.

Main Results:

  • Evidence suggests P-glycoprotein functions as an energy-dependent drug efflux pump.
  • Overexpression of P-glycoprotein is a frequent alteration in multidrug-resistant cells.
  • Pharmacological strategies targeting P-glycoprotein may offer a way to overcome clinical drug resistance.

Conclusions:

  • P-glycoprotein is implicated as a key mediator of multidrug resistance in cancer.
  • Targeting the P-glycoprotein efflux pump presents a potential therapeutic strategy.
  • Circumventing P-glycoprotein-mediated resistance could improve the efficacy of chemotherapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...